Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Crystal structures of Mycobacterium tuberculosis KasA show mode of action within cell wall biosynthesis and its inhibition by thiolactomycin.

Luckner SR, Machutta CA, Tonge PJ, Kisker C.

Structure. 2009 Jul 15;17(7):1004-13. doi: 10.1016/j.str.2009.04.012.

2.

KasA, another brick in the mycobacterial cell wall.

Swanson S, Gokulan K, Sacchettini JC.

Structure. 2009 Jul 15;17(7):914-5. doi: 10.1016/j.str.2009.06.006. No abstract available.

3.

Purification and biochemical characterization of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthases KasA and KasB.

Schaeffer ML, Agnihotri G, Volker C, Kallender H, Brennan PJ, Lonsdale JT.

J Biol Chem. 2001 Dec 14;276(50):47029-37. Epub 2001 Oct 12.

4.

X-ray crystal structure of Mycobacterium tuberculosis beta-ketoacyl acyl carrier protein synthase II (mtKasB).

Sridharan S, Wang L, Brown AK, Dover LG, Kremer L, Besra GS, Sacchettini JC.

J Mol Biol. 2007 Feb 16;366(2):469-80. Epub 2006 Nov 7.

5.
6.

Development of a scintillation proximity assay for the Mycobacterium tuberculosis KasA and KasB enzymes involved in mycolic acid biosynthesis.

Schaeffer ML, Carson JD, Kallender H, Lonsdale JT.

Tuberculosis (Edinb). 2004;84(6):353-60.

PMID:
15525558
7.

Crystal structure of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III.

Scarsdale JN, Kazanina G, He X, Reynolds KA, Wright HT.

J Biol Chem. 2001 Jun 8;276(23):20516-22. Epub 2001 Mar 8.

8.

Crystal structure of a substrate complex of Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III (FabH) with lauroyl-coenzyme A.

Musayev F, Sachdeva S, Scarsdale JN, Reynolds KA, Wright HT.

J Mol Biol. 2005 Mar 11;346(5):1313-21. Epub 2005 Jan 20.

PMID:
15713483
9.

Structural basis for the recognition of mycolic acid precursors by KasA, a condensing enzyme and drug target from Mycobacterium tuberculosis.

Schiebel J, Kapilashrami K, Fekete A, Bommineni GR, Schaefer CM, Mueller MJ, Tonge PJ, Kisker C.

J Biol Chem. 2013 Nov 22;288(47):34190-204. doi: 10.1074/jbc.M113.511436. Epub 2013 Oct 9.

10.

Thiolactomycin and related analogues as novel anti-mycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis.

Kremer L, Douglas JD, Baulard AR, Morehouse C, Guy MR, Alland D, Dover LG, Lakey JH, Jacobs WR Jr, Brennan PJ, Minnikin DE, Besra GS.

J Biol Chem. 2000 Jun 2;275(22):16857-64.

11.
12.

Molecular dynamics of Mycobacterium tuberculosis KasA: implications for inhibitor and substrate binding and consequences for drug design.

Schaefer B, Kisker C, Sotriffer CA.

J Comput Aided Mol Des. 2011 Nov;25(11):1053-69. doi: 10.1007/s10822-011-9483-4. Epub 2011 Nov 11.

PMID:
22076471
13.

The β-ketoacyl-ACP synthase from Mycobacterium tuberculosis as potential drug targets.

Singh V, Mani I, Chaudhary DK, Somvanshi P.

Curr Med Chem. 2011;18(9):1318-24. Review.

PMID:
21370994
14.

Probing the mechanism of the Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III mtFabH: factors influencing catalysis and substrate specificity.

Brown AK, Sridharan S, Kremer L, Lindenberg S, Dover LG, Sacchettini JC, Besra GS.

J Biol Chem. 2005 Sep 16;280(37):32539-47. Epub 2005 Jul 22.

15.

The Mycobacterium tuberculosis beta-ketoacyl-acyl carrier protein synthase III activity is inhibited by phosphorylation on a single threonine residue.

Veyron-Churlet R, Molle V, Taylor RC, Brown AK, Besra GS, Zanella-Cléon I, Fütterer K, Kremer L.

J Biol Chem. 2009 Mar 6;284(10):6414-24. doi: 10.1074/jbc.M806537200. Epub 2008 Dec 11.

16.

Biphenyl-based analogues of thiolactomycin, active against Mycobacterium tuberculosis mtFabH fatty acid condensing enzyme.

Senior SJ, Illarionov PA, Gurcha SS, Campbell IB, Schaeffer ML, Minnikin DE, Besra GS.

Bioorg Med Chem Lett. 2003 Nov 3;13(21):3685-8.

PMID:
14552758
17.

Drugs that inhibit mycolic acid biosynthesis in Mycobacterium tuberculosis.

Schroeder EK, de Souza N, Santos DS, Blanchard JS, Basso LA.

Curr Pharm Biotechnol. 2002 Sep;3(3):197-225. Review.

PMID:
12164478
18.

Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis.

Slayden RA, Lee RE, Armour JW, Cooper AM, Orme IM, Brennan PJ, Besra GS.

Antimicrob Agents Chemother. 1996 Dec;40(12):2813-9.

19.

Slow onset inhibition of bacterial beta-ketoacyl-acyl carrier protein synthases by thiolactomycin.

Machutta CA, Bommineni GR, Luckner SR, Kapilashrami K, Ruzsicska B, Simmerling C, Kisker C, Tonge PJ.

J Biol Chem. 2010 Feb 26;285(9):6161-9. doi: 10.1074/jbc.M109.077909. Epub 2009 Dec 16.

20.

Inhibition of a Mycobacterium tuberculosis beta-ketoacyl ACP synthase by isoniazid.

Mdluli K, Slayden RA, Zhu Y, Ramaswamy S, Pan X, Mead D, Crane DD, Musser JM, Barry CE 3rd.

Science. 1998 Jun 5;280(5369):1607-10.

Supplemental Content

Support Center